AKBAAkebia Therapeutics, Inc.

$365M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M-18.5% YoY

Gross Profit

$30M91.7% margin

Operating Income

-$15M-45.8% margin

Net Income

-$18M-55.2% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-42.0%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$225M

Total Liabilities

$253M

Stockholders' Equity

-$27M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$40M	-18.5%
Gross Profit	$30M	$20M	+50.8%
Operating Income	-$15M	-$26M	+41.6%
Net Income	-$18M	-$27M	+33.1%

Revenue Segments

Product

$31M95%

License Collaboration And Other Revenue

$2M5%

AKBA Q1 2024 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena